Anaplastic Lymphoma Kinase in Cutaneous Malignancies
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been implicated in the pathogenesis of a variety of neoplasms. As suggested by its name, ALK was first described as part of a translocation product in cases of anaplastic large-cell lymphoma, with other genetic and cytogenetic A...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/9/9/123 |
| _version_ | 1797707151245836288 |
|---|---|
| author | Severine Cao Vinod E. Nambudiri |
| author_facet | Severine Cao Vinod E. Nambudiri |
| author_sort | Severine Cao |
| collection | DOAJ |
| description | Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been implicated in the pathogenesis of a variety of neoplasms. As suggested by its name, ALK was first described as part of a translocation product in cases of anaplastic large-cell lymphoma, with other genetic and cytogenetic ALK mutations subsequently coming to attention in the development of many other hematologic and solid organ malignancies. ALK has now been shown to play a role in the pathogenesis of several cutaneous malignancies, including secondary cutaneous systemic anaplastic large-cell lymphoma (ALCL) and primary cutaneous ALCL, melanoma, spitzoid tumors, epithelioid fibrous histiocytoma, Merkel cell carcinoma, and basal cell carcinoma. The characterization of ALK-positivity in these cutaneous malignancies presents exciting opportunities for utilizing ALK-targeted inhibitors in the treatment of these diseases. |
| first_indexed | 2024-03-12T06:02:02Z |
| format | Article |
| id | doaj.art-aec83d27a4ae4f448991909a0bfce8e7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:02:02Z |
| publishDate | 2017-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-aec83d27a4ae4f448991909a0bfce8e72023-09-03T04:04:29ZengMDPI AGCancers2072-66942017-09-019912310.3390/cancers9090123cancers9090123Anaplastic Lymphoma Kinase in Cutaneous MalignanciesSeverine Cao0Vinod E. Nambudiri1Harvard Medical School, Boston, MA 02115, USAHarvard Medical School, Boston, MA 02115, USAAnaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been implicated in the pathogenesis of a variety of neoplasms. As suggested by its name, ALK was first described as part of a translocation product in cases of anaplastic large-cell lymphoma, with other genetic and cytogenetic ALK mutations subsequently coming to attention in the development of many other hematologic and solid organ malignancies. ALK has now been shown to play a role in the pathogenesis of several cutaneous malignancies, including secondary cutaneous systemic anaplastic large-cell lymphoma (ALCL) and primary cutaneous ALCL, melanoma, spitzoid tumors, epithelioid fibrous histiocytoma, Merkel cell carcinoma, and basal cell carcinoma. The characterization of ALK-positivity in these cutaneous malignancies presents exciting opportunities for utilizing ALK-targeted inhibitors in the treatment of these diseases.https://www.mdpi.com/2072-6694/9/9/123anaplastic lymphoma kinasecutaneous malignancyanaplastic large cell lymphomacrizotinib |
| spellingShingle | Severine Cao Vinod E. Nambudiri Anaplastic Lymphoma Kinase in Cutaneous Malignancies Cancers anaplastic lymphoma kinase cutaneous malignancy anaplastic large cell lymphoma crizotinib |
| title | Anaplastic Lymphoma Kinase in Cutaneous Malignancies |
| title_full | Anaplastic Lymphoma Kinase in Cutaneous Malignancies |
| title_fullStr | Anaplastic Lymphoma Kinase in Cutaneous Malignancies |
| title_full_unstemmed | Anaplastic Lymphoma Kinase in Cutaneous Malignancies |
| title_short | Anaplastic Lymphoma Kinase in Cutaneous Malignancies |
| title_sort | anaplastic lymphoma kinase in cutaneous malignancies |
| topic | anaplastic lymphoma kinase cutaneous malignancy anaplastic large cell lymphoma crizotinib |
| url | https://www.mdpi.com/2072-6694/9/9/123 |
| work_keys_str_mv | AT severinecao anaplasticlymphomakinaseincutaneousmalignancies AT vinodenambudiri anaplasticlymphomakinaseincutaneousmalignancies |